Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Larimar Therapeutics (LRMR) EBITDA (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed EBITDA for 7 consecutive years, with -$6.1 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, EBITDA rose 58.31% year-over-year to -$6.1 million, compared with a TTM value of -$23.1 million through Dec 2019, up 62.29%, and an annual FY2024 reading of -$80.5 million, down 118.63% over the prior year.
  • EBITDA was -$6.1 million for Q4 2019 at Larimar Therapeutics, down from -$274000.0 in the prior quarter.
  • Across five years, EBITDA topped out at -$274000.0 in Q3 2019 and bottomed at -$23.3 million in Q4 2015.
  • Average EBITDA over 5 years is -$13.4 million, with a median of -$14.0 million recorded in 2015.
  • The sharpest move saw EBITDA crashed 202.29% in 2015, then surged 98.18% in 2019.
  • Year by year, EBITDA stood at -$23.3 million in 2015, then surged by 55.23% to -$10.5 million in 2016, then decreased by 25.47% to -$13.1 million in 2017, then fell by 11.13% to -$14.6 million in 2018, then skyrocketed by 58.31% to -$6.1 million in 2019.
  • Business Quant data shows EBITDA for LRMR at -$6.1 million in Q4 2019, -$274000.0 in Q3 2019, and -$3.7 million in Q2 2019.